Toggle menu

DASH Trial

Start date:
June 2019

Why?

Medications to ‘thin’ the blood can have an unwanted effect on strokes caused by bleeding in the brain. Controlling bleeding is crucial in the first few hours after stroke but there is still uncertainty over the best course of treatment.

 

What?

DASH is a randomised clinical trial investigating a treatment to reverse the effects of blood-thinning medications.

 

https://clinicaltrials.gov/ct2/show/NCT03696121

Research Team

Allan MacRaild

Stroke Lead Research Nurse

Seona Burgess

Senior Stroke Research Nurse

Pat Taylor

Senior Stroke Research Nurse

Rachel O'Brien

Lead Research Nurse

Julia Grahamslaw

Lead Research Nurse

Fiona McCurrach

Senior Research Nurse

More EMERGE Trials

The RECOVERY Trial

Randomised Evaluation of COVID-19 Therapy

To determine the association between high-sensitivity cardiac troponin concentration and obstructive coronary artery disease in patients presenting to the Emergency Department with suspected acute coronary syndrome and cardiac troponin concentration within the normal reference range using CTCA.

Read more

PRECISE-CTCA Trial

To determine the association between high-sensitivity cardiac troponin concentration and obstructive coronary artery disease in patients presenting to the Emergency Department with suspected acute coronary syndrome and cardiac troponin concentration within the normal reference range using CTCA.